Marina Settles Trademark Dispute with Mirina, Will Retain its Name | GenomeWeb

By Doug Macron

Marina Biotech and Mirina have settled their trademark dispute over the similarity of their names, with each company agreeing to drop all claims and counterclaims and bear their own attorney fees and court costs.

Specific terms of the settlement were not made public, but Marina President and CEO Michael French confirmed to Gene Silencing News that his company would continue to use its name and that “no compensation was exchanged between the parties.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.